Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sequencing Firm Element Biosciences Closes $276M Series C Financing Round

NEW YORK – DNA sequencing technology firm Element Biosciences said on Tuesday that it has closed a $276 million Series C financing round.

New investors Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Morgan Stanley's Counterpoint Global, and T. Rowe Price joined existing investors Fidelity Management & Research, Foresite Capital, JS Capital Management, RA Capital Advisors, and Venrock for this round.

Proceeds from the financing will be used to scale the firm's commercial organization and to fund the launch of its next-generation sequencing platform.

"Element has developed a differentiated, modular, platform-based approach that reinvents all aspects of a DNA sequencing solution," said John Stuelpnagel, chairman of the firm's board of directors, in a statement. "The company has the vision and executional roadmap needed to support current and emerging opportunities in the genomics research market."

The round brings Element's total fundraising to approximately $400 million. The San Diego-based firm raised $80 million in Series B financing in January 2020.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.